Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
04/2003
04/24/2003WO2003033507A1 Benzylmalonic acid derivatives and proteasome inhibitors contaiing the same
04/24/2003WO2003033506A1 Aminoborane acid derivative and proteasome inhibitory drug containing the same
04/24/2003WO2003033502A1 Bicyclic oxopyridine and oxopyrimidine derivatives
04/24/2003WO2003033497A1 Tetracyclic azaindoles and -indolines having serotonin 5-ht2c activity
04/24/2003WO2003033496A1 Beta-carbolin derivatives as ptp-inhibitors
04/24/2003WO2003033495A1 Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
04/24/2003WO2003033493A1 ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR δ
04/24/2003WO2003033489A1 Piperidine derivatives, process for preparation thereof, and pharmaceutical composition for alzheimer's disease containing the same
04/24/2003WO2003033486A1 Novel substituted 4-phenyl-4-[1h-imidazol-2-yl]-piperidine derivatives and their use as selective non-peptide delta opioid agonists
04/24/2003WO2003033484A1 Substituted piperazine cyclohexane carboxilic acid amides and the use thereof
04/24/2003WO2003033483A1 Biphenylcarboxylic amide derivatives as p38 kinase inhibitors
04/24/2003WO2003033482A1 Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors
04/24/2003WO2003033481A1 Benzoxazine and benzothiazine derivatives and parmaceutical compositions containing them
04/24/2003WO2003033480A1 Lactam derivatives as antagonists for human 11cby receptors
04/24/2003WO2003033476A1 Pyrimidinones as melanin concentrating hormone receptor 1
04/24/2003WO2003033470A1 Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain
04/24/2003WO2003033466A1 Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same
04/24/2003WO2003033457A1 Biphenyl-derivatives as p38-kinase inhibitors
04/24/2003WO2003033456A1 NOVEL β-PHENYL-α-OXYSUBSTITUTED PROPIONIC DERIVATIVES: PROCESS FOR ITS PREPARATION AND THEIR USE IN THE PREPARATION OF PHARMACEUTICALLY IMPORTANT COMPOUNDS
04/24/2003WO2003033048A2 Drug delivery system for conscious sedation
04/24/2003WO2003033016A1 Use of neurotrophic factors for treating neurodegenerative diseases and cancer
04/24/2003WO2003033015A1 USE OF gp130 ACTIVATORS IN DIABETIC NEUROPATHY
04/24/2003WO2003033010A1 Cyclosporin analogs for the treatment of autoimmune diseases
04/24/2003WO2003033002A1 Intracellular calcium concentration increase inhibitors
04/24/2003WO2003032997A1 Pyrimidine derivatives, pharmaceutical agent containing said compounds, use and method for making same
04/24/2003WO2003032996A1 Imidazo (4,3-e)-1,2,4-triazolo(1,5-c) pyrimidines as adenosine a2a receptor antagonists
04/24/2003WO2003032995A1 Rosuvastatin in pre demented states
04/24/2003WO2003032993A1 Use of phosphorodiesterase iv inhibitors
04/24/2003WO2003032992A1 Use of inhibitors of the y2 receptor of neuropeptide y in the treatment of alcoholism
04/24/2003WO2003032991A1 N-aroyl piperazine derivatives as orexin receptor antagonists
04/24/2003WO2003032990A2 Polymer conjugates of opioid antagonists
04/24/2003WO2003032989A1 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors
04/24/2003WO2003032987A1 2'-methyl-5'-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032986A1 2' -methyl-5-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032982A1 Bis-heteroaryl alkanes as therapeutic agents
04/24/2003WO2003032981A1 4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes
04/24/2003WO2003032980A1 5'-carbamoyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032974A2 Use of sulfonamide derivatives as pharmaceuticals compounds
04/24/2003WO2003032973A2 Composition comprising paracetamol and a bitterness masking component
04/24/2003WO2003032972A1 5’-carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032971A1 5’-acylamino-1,1’-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032970A1 5'-carbamoyl-2'-methyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032969A2 Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications
04/24/2003WO2003032964A2 Gap junctions and endothelial-derived hyperpolarizing factor (edhf)
04/24/2003WO2003032960A1 Percutaneous absorption preparations
04/24/2003WO2003032955A1 Highly compressible ethylcellulose for tableting
04/24/2003WO2003032921A2 Treatment of neurodegenerative diseases and cancer of the brain
04/24/2003WO2003032918A2 Treatment of infectious disease using interleukin-1 beta converting enzyme (ice)/ced-3 family inhibitors
04/24/2003WO2003032916A2 Organosulfur inhibitors of tyrosine phosphatases
04/24/2003WO2003032912A2 Treatment of cns disorders using cns target modulators
04/24/2003WO2003032910A2 Carbinols for the treatment of neuropathic dysfunction
04/24/2003WO2003032897A2 Azabicyclic compounds for the treatment of fibromyalgia syndrome
04/24/2003WO2003032894A2 Method of monitoring neuroprotective treatment
04/24/2003WO2003032735A1 Remodeling of tissues and organs
04/24/2003WO2003004049A3 Use of polyclonal anti-hiv goat serum as a therapeutic agent
04/24/2003WO2002102376A8 ORALLY DELIVERABLE PHARMACEUTICAL COMPOSITION COMPRISING AN ACTIVE COMPOUND HAVING AN AMINOSULFONYL GROUP (cox-2 INHIBITOR), A POLYETHYLENE GLYCOL AND A FREE-RADICAL SCAVENGING ANTIOXIDANT
04/24/2003WO2002100437A3 Ophthalmic compositions comprising hyaluronic acid
04/24/2003WO2002098907A3 Cation conducting gabaa receptors and their use
04/24/2003WO2002089841A3 Method of preventing cell death using antibodies to neural thread proteins
04/24/2003WO2002088134A3 Antipsychotic aminomethyl derivatives of 1,3,7,8-tetrahydro-6,9-dioxa-1,3-diaza-cyclopenta[a]-naphthalen-2-one
04/24/2003WO2002074959A3 Human leucine-rich repeat containing protein expressed predominately in nervous system tissues, hlrrns1
04/24/2003WO2002072822A3 Als2 gene and amyotrophic lateral sclerosis type 2
04/24/2003WO2002064748A8 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
04/24/2003WO2002062299A3 Improved controlled release oral dosage form
04/24/2003WO2002057483A3 Method of identifying modulators of nogo-functions
04/24/2003WO2002057259A3 Pyrazole compounds useful as protein kinase inhibitors
04/24/2003WO2002056875A3 Method of treatment of dopamine-related dysfunction through administration of a full d1 dopamine receptor agonist and with no induction of tolerance
04/24/2003WO2002055552A3 Soluble cyclic analogues of beta amyloid peptide
04/24/2003WO2002046383A3 Protein modification and maintenance molecules
04/24/2003WO2002045710A9 Methods for treating neuropsychiatric disorders with nmda receptor antagonists
04/24/2003WO2002043741A3 Methylenetetrahydrofolate reductase inhibitors and use thereof
04/24/2003WO2002030980A3 Use of anti-human integrin alpha d antibodies to treat spinal cord injury
04/24/2003WO2002026825A3 G-protein coupled receptors
04/24/2003WO2002018585A8 Packaging of positive-strand rna virus replicon particles
04/24/2003WO2002016615A3 Crystal structure of dimethylarginine dimethylaminohydrolase and arginine deiminase
04/24/2003WO2002016408A3 Gpe analogs
04/24/2003WO2002004513A3 Down syndrome critical region 1-like 1 proteins
04/24/2003WO2002000878A3 Human msp1 mitochondrial dynamin, its msp1-x isoforms, and their therapeutic use
04/24/2003WO2001075440A3 Schizophrenia related genes
04/24/2003US20030078442 Crystalline base of citalopram
04/24/2003US20030078405 47 human secreted proteins
04/24/2003US20030078373 Chaperone fragments
04/24/2003US20030078303 Methods of treating and preventing sexual dysfunction using (+) sibutramine in combination with phosphodiesterase inhibitors
04/24/2003US20030078300 Fused bicyclic or tricyclic amino acids
04/24/2003US20030078299 Anti-cancer nitro- and thia-fatty acids
04/24/2003US20030078289 Indole carboxylic acids as thyroid receptor ligands
04/24/2003US20030078288 Indole derivatives
04/24/2003US20030078286 For therapy of central nervous system disorders such as anxiety, depression, motor disorders
04/24/2003US20030078284 Materials and methods for the treatment of depression
04/24/2003US20030078280 Macroheterocylic compounds useful as kinase inhibitors
04/24/2003US20030078279 For therapy and prophylaxis of pain, central nervous system disorder or the like in mammalian subjects
04/24/2003US20030078278 Spiropiperidine compounds as ligands for ORL-1 receptor
04/24/2003US20030078275 For therapy of cancer, diabetes and Alzheimer's disease
04/24/2003US20030078274 Method of reducing neuronal injury or apoptosis
04/24/2003US20030078273 Heterocyclic amine, a phenylazacycloalkane, a cabergoline, or an aromatic bicyclic amine active agent
04/24/2003US20030078271 Pyrimidine and indolone derivatives
04/24/2003US20030078270 Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
04/24/2003US20030078268 Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-6H-5-oxa-1-aza-phenanthrene
04/24/2003US20030078265 Inhibitors of nitric oxide synthase (nos)
04/24/2003US20030078259 Nicotinic acetylcholine receptor activators; treating neurodegenerative disorders
1 ... 1222 1223 1224 1225 1226 1227 1228 1229 1230 1231 1232 1233 1234 1235 1236 1237 1238 1239 1240 1241 1242 ... 1833